Proteomic analysis of Intercept-treated platelets.
Identifieur interne : 000829 ( Main/Exploration ); précédent : 000828; suivant : 000830Proteomic analysis of Intercept-treated platelets.
Auteurs : Michel Prudent [Suisse] ; David Crettaz ; Julien Delobel ; Jean-Daniel Tissot ; Niels LionSource :
- Journal of proteomics [ 1876-7737 ] ; 2012.
Descripteurs français
- KwdFr :
- Buffy coat (cytologie), Buffy coat (microbiologie), Buffy coat (métabolisme), Femelle (MeSH), Furocoumarines (pharmacologie), Humains (MeSH), Mâle (MeSH), Photosensibilisants (pharmacologie), Plaquettes (cytologie), Plaquettes (microbiologie), Plaquettes (métabolisme), Protéines du sang (métabolisme), Protéome (métabolisme), Protéomique (MeSH), Stérilisation (méthodes), Viabilité microbienne (effets des médicaments et des substances chimiques).
- MESH :
- cytologie : Buffy coat, Plaquettes.
- effets des médicaments et des substances chimiques : Viabilité microbienne.
- microbiologie : Buffy coat, Plaquettes.
- métabolisme : Buffy coat, Plaquettes, Protéines du sang, Protéome.
- méthodes : Stérilisation.
- pharmacologie : Furocoumarines, Photosensibilisants.
- Femelle, Humains, Mâle, Protéomique.
English descriptors
- KwdEn :
- Blood Buffy Coat (cytology), Blood Buffy Coat (metabolism), Blood Buffy Coat (microbiology), Blood Platelets (cytology), Blood Platelets (metabolism), Blood Platelets (microbiology), Blood Proteins (metabolism), Female (MeSH), Furocoumarins (pharmacology), Humans (MeSH), Male (MeSH), Microbial Viability (drug effects), Photosensitizing Agents (pharmacology), Proteome (metabolism), Proteomics (MeSH), Sterilization (methods).
- MESH :
- chemical , metabolism : Blood Proteins, Proteome.
- cytology : Blood Buffy Coat, Blood Platelets.
- drug effects : Microbial Viability.
- metabolism : Blood Buffy Coat, Blood Platelets.
- methods : Sterilization.
- microbiology : Blood Buffy Coat, Blood Platelets.
- chemical , pharmacology : Furocoumarins, Photosensitizing Agents.
- Female, Humans, Male, Proteomics.
Abstract
In the past decades, transfusion medicine has been driven by the quest for increased safety against transfusion-transmitted infections, mainly by better donor selection and by the development of improved serological and nucleic-acid-based screening assays. Recently, pathogen reduction technologies became available and started to be implemented in several countries, with the primary goal to fight against bacterial contamination of blood products, a rare but dramatic event against which there was no definitive measure. Though pathogen reduction technologies represent a quantum leap in transfusion safety, the biomedical efficacy of platelet concentrates (PCs) treated with various pathogen reduction techniques has been recently questioned by clinical studies. Here, a gel-based proteomic analysis of PCs (n=5), Intercept-treated or untreated, from pooled buffy-coat (10 donors per PC) at Days 1, 2 and 8, shows that the Intercept process that is the most widespread pathogen reduction technique to date, has relatively low impact on the proteome of treated platelets: the process induces modifications of DJ-1 protein, glutaredoxin 5, and G(i)alpha 2 protein. As for the impact of storage, chloride intracellular channel protein 4 (CLIC4) and actin increased independently of Intercept treatment during storage. Whereas alteration of the DJ-1 protein and glutaredoxin 5 points out an oxidative stress-associated lesion, modification of G(i)alpha2 directly connects a possible Intercept-associated lesion to haemostatic properties of Intercept-treated platelets. This article is part of a Special Issue entitled: Integrated omics.
DOI: 10.1016/j.jprot.2012.07.008
PubMed: 22813878
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Proteomic analysis of Intercept-treated platelets.</title><author><name sortKey="Prudent, Michel" sort="Prudent, Michel" uniqKey="Prudent M" first="Michel" last="Prudent">Michel Prudent</name><affiliation wicri:level="3"><nlm:affiliation>Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Service Régional Vaudois de Transfusion Sanguine, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Crettaz, David" sort="Crettaz, David" uniqKey="Crettaz D" first="David" last="Crettaz">David Crettaz</name></author><author><name sortKey="Delobel, Julien" sort="Delobel, Julien" uniqKey="Delobel J" first="Julien" last="Delobel">Julien Delobel</name></author><author><name sortKey="Tissot, Jean Daniel" sort="Tissot, Jean Daniel" uniqKey="Tissot J" first="Jean-Daniel" last="Tissot">Jean-Daniel Tissot</name></author><author><name sortKey="Lion, Niels" sort="Lion, Niels" uniqKey="Lion N" first="Niels" last="Lion">Niels Lion</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22813878</idno><idno type="pmid">22813878</idno><idno type="doi">10.1016/j.jprot.2012.07.008</idno><idno type="wicri:Area/Main/Corpus">000821</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000821</idno><idno type="wicri:Area/Main/Curation">000821</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000821</idno><idno type="wicri:Area/Main/Exploration">000821</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Proteomic analysis of Intercept-treated platelets.</title><author><name sortKey="Prudent, Michel" sort="Prudent, Michel" uniqKey="Prudent M" first="Michel" last="Prudent">Michel Prudent</name><affiliation wicri:level="3"><nlm:affiliation>Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Service Régional Vaudois de Transfusion Sanguine, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Crettaz, David" sort="Crettaz, David" uniqKey="Crettaz D" first="David" last="Crettaz">David Crettaz</name></author><author><name sortKey="Delobel, Julien" sort="Delobel, Julien" uniqKey="Delobel J" first="Julien" last="Delobel">Julien Delobel</name></author><author><name sortKey="Tissot, Jean Daniel" sort="Tissot, Jean Daniel" uniqKey="Tissot J" first="Jean-Daniel" last="Tissot">Jean-Daniel Tissot</name></author><author><name sortKey="Lion, Niels" sort="Lion, Niels" uniqKey="Lion N" first="Niels" last="Lion">Niels Lion</name></author></analytic><series><title level="j">Journal of proteomics</title><idno type="eISSN">1876-7737</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Buffy Coat (cytology)</term><term>Blood Buffy Coat (metabolism)</term><term>Blood Buffy Coat (microbiology)</term><term>Blood Platelets (cytology)</term><term>Blood Platelets (metabolism)</term><term>Blood Platelets (microbiology)</term><term>Blood Proteins (metabolism)</term><term>Female (MeSH)</term><term>Furocoumarins (pharmacology)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Microbial Viability (drug effects)</term><term>Photosensitizing Agents (pharmacology)</term><term>Proteome (metabolism)</term><term>Proteomics (MeSH)</term><term>Sterilization (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Buffy coat (cytologie)</term><term>Buffy coat (microbiologie)</term><term>Buffy coat (métabolisme)</term><term>Femelle (MeSH)</term><term>Furocoumarines (pharmacologie)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Photosensibilisants (pharmacologie)</term><term>Plaquettes (cytologie)</term><term>Plaquettes (microbiologie)</term><term>Plaquettes (métabolisme)</term><term>Protéines du sang (métabolisme)</term><term>Protéome (métabolisme)</term><term>Protéomique (MeSH)</term><term>Stérilisation (méthodes)</term><term>Viabilité microbienne (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Proteins</term><term>Proteome</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Buffy coat</term><term>Plaquettes</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Blood Buffy Coat</term><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microbial Viability</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Viabilité microbienne</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Blood Buffy Coat</term><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Sterilization</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Buffy coat</term><term>Plaquettes</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Blood Buffy Coat</term><term>Blood Platelets</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Buffy coat</term><term>Plaquettes</term><term>Protéines du sang</term><term>Protéome</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Stérilisation</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Furocoumarines</term><term>Photosensibilisants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Furocoumarins</term><term>Photosensitizing Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Proteomics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Protéomique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the past decades, transfusion medicine has been driven by the quest for increased safety against transfusion-transmitted infections, mainly by better donor selection and by the development of improved serological and nucleic-acid-based screening assays. Recently, pathogen reduction technologies became available and started to be implemented in several countries, with the primary goal to fight against bacterial contamination of blood products, a rare but dramatic event against which there was no definitive measure. Though pathogen reduction technologies represent a quantum leap in transfusion safety, the biomedical efficacy of platelet concentrates (PCs) treated with various pathogen reduction techniques has been recently questioned by clinical studies. Here, a gel-based proteomic analysis of PCs (n=5), Intercept-treated or untreated, from pooled buffy-coat (10 donors per PC) at Days 1, 2 and 8, shows that the Intercept process that is the most widespread pathogen reduction technique to date, has relatively low impact on the proteome of treated platelets: the process induces modifications of DJ-1 protein, glutaredoxin 5, and G(i)alpha 2 protein. As for the impact of storage, chloride intracellular channel protein 4 (CLIC4) and actin increased independently of Intercept treatment during storage. Whereas alteration of the DJ-1 protein and glutaredoxin 5 points out an oxidative stress-associated lesion, modification of G(i)alpha2 directly connects a possible Intercept-associated lesion to haemostatic properties of Intercept-treated platelets. This article is part of a Special Issue entitled: Integrated omics.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22813878</PMID><DateCompleted><Year>2013</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2016</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-7737</ISSN><JournalIssue CitedMedium="Internet"><Volume>76 Spec No.</Volume><PubDate><Year>2012</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of proteomics</Title><ISOAbbreviation>J Proteomics</ISOAbbreviation></Journal><ArticleTitle>Proteomic analysis of Intercept-treated platelets.</ArticleTitle><Pagination><MedlinePgn>316-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jprot.2012.07.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1874-3919(12)00538-6</ELocationID><Abstract><AbstractText>In the past decades, transfusion medicine has been driven by the quest for increased safety against transfusion-transmitted infections, mainly by better donor selection and by the development of improved serological and nucleic-acid-based screening assays. Recently, pathogen reduction technologies became available and started to be implemented in several countries, with the primary goal to fight against bacterial contamination of blood products, a rare but dramatic event against which there was no definitive measure. Though pathogen reduction technologies represent a quantum leap in transfusion safety, the biomedical efficacy of platelet concentrates (PCs) treated with various pathogen reduction techniques has been recently questioned by clinical studies. Here, a gel-based proteomic analysis of PCs (n=5), Intercept-treated or untreated, from pooled buffy-coat (10 donors per PC) at Days 1, 2 and 8, shows that the Intercept process that is the most widespread pathogen reduction technique to date, has relatively low impact on the proteome of treated platelets: the process induces modifications of DJ-1 protein, glutaredoxin 5, and G(i)alpha 2 protein. As for the impact of storage, chloride intracellular channel protein 4 (CLIC4) and actin increased independently of Intercept treatment during storage. Whereas alteration of the DJ-1 protein and glutaredoxin 5 points out an oxidative stress-associated lesion, modification of G(i)alpha2 directly connects a possible Intercept-associated lesion to haemostatic properties of Intercept-treated platelets. This article is part of a Special Issue entitled: Integrated omics.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prudent</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service Régional Vaudois de Transfusion Sanguine, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crettaz</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Delobel</LastName><ForeName>Julien</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>Jean-Daniel</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Lion</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Proteomics</MedlineTA><NlmUniqueID>101475056</NlmUniqueID><ISSNLinking>1874-3919</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011564">Furocoumarins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017319">Photosensitizing Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058621" MajorTopicYN="N">Blood Buffy Coat</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011564" MajorTopicYN="N">Furocoumarins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050296" MajorTopicYN="N">Microbial Viability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017319" MajorTopicYN="N">Photosensitizing Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013242" MajorTopicYN="N">Sterilization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>07</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22813878</ArticleId><ArticleId IdType="pii">S1874-3919(12)00538-6</ArticleId><ArticleId IdType="doi">10.1016/j.jprot.2012.07.008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country><region><li>Canton de Vaud</li></region><settlement><li>Lausanne</li></settlement></list><tree><noCountry><name sortKey="Crettaz, David" sort="Crettaz, David" uniqKey="Crettaz D" first="David" last="Crettaz">David Crettaz</name><name sortKey="Delobel, Julien" sort="Delobel, Julien" uniqKey="Delobel J" first="Julien" last="Delobel">Julien Delobel</name><name sortKey="Lion, Niels" sort="Lion, Niels" uniqKey="Lion N" first="Niels" last="Lion">Niels Lion</name><name sortKey="Tissot, Jean Daniel" sort="Tissot, Jean Daniel" uniqKey="Tissot J" first="Jean-Daniel" last="Tissot">Jean-Daniel Tissot</name></noCountry><country name="Suisse"><region name="Canton de Vaud"><name sortKey="Prudent, Michel" sort="Prudent, Michel" uniqKey="Prudent M" first="Michel" last="Prudent">Michel Prudent</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= GlutaredoxinV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22813878
|texte= Proteomic analysis of Intercept-treated platelets.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22813878" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GlutaredoxinV1
| This area was generated with Dilib version V0.6.37. |  |